Parkinsons Disease Therapeutics Market Synopsis:
Parkinsons Disease Therapeutics Market Size Was Valued at USD 5.46 Billion in 2023, and is Projected to Reach USD 10.12 Billion by 2032, Growing at a CAGR of 7.1% From 2024-2032
The Parkinson’s Disease Therapeutics Market consequently describes the trade that is involved with the creation, manufacture and selling of products that are intended to alleviate the symptoms of Parkinson’s disease, a disease that is neurological in nature and causes difficulty controlling the body’s movements. This market also includes other drugs such as dopamine agonists, MAO-B inhibitors, COMT inhibitors and other anti-Parkinson treatments aimed at managing symptom and helping the patient to lead a better life. It also includes things such as deep brain stimulation (DBS) devices and patient monitoring systems. This market has been fueled by the growing number of people affected by Parkinson’s disease, the continuing development of new treatment methods, and relentless research into disease-altering agents.
The market for Parkinson’s Disease Therapeutics has been growing more dynamic in response to the empowering of the symptoms and progression of the disease among healthcare providers and pharma companies. Parkinson’s disease is a progressive neurologic disorder with motor manifestations including tremor, rigidity, and akinesia that causes a very negative influence on the patient’s quality of life. The sizing located has recently experienced progression about each medicinal and top non-medicinal approaches such as DBS and gene treatment. The continually rising incidence of Parkinson’s disease, coupled with the aging population worldwide, has consumers seeking out better therapeutic options. Further, continued investigation has resulted in new drug formulation and delivery science which worth trying to enhance the patient compliance rate and treatment outcomes.
It is important to state that there are still problems which exist in the given market, for example high treatment costs, the lack of medical facilities, and the necessity to choose an individual method of the treatment. Further, current studies and related studies are likely to show effective data and live trials possibly offering more therapeutic action, which is beneficial. In addition to research funding, regulatory approvals and partnerships between the pharmaceutical industry and academic centers have become other dominant driving forces in Parkinson’s disease treatment. The Parkinson’s Disease Therapeutics Market being very much centred towards early diagnostics, development of disease modifying therapies, and better patient management, it is set for a steady growth in the future owing to the incorporation of more sophisticated technologies, research grants, as well as the growing need for good treatment.
.webp)
Parkinsons Disease Therapeutics Market Trend Analysis:
Expanding Opportunities in the Parkinson's Disease Therapeutics Market
- The market for therapeutics for Parkinson’s disease is growing based on the increasing incidence of disease particularly, among aging population. Parkinson, a progressive neurologic disease associated with the loss of dopaminergic neurons in the substantia nigra, presented by such motor impairments as tremor, rigidity, and bradykinesia is increasingly prevailing. According to demographics, there is growing need for treatments that will help improve patient outcomes and reduce suffering from diseases. The market is responding through modern treatment such as dopamine agonists, MAO-B inhibitors, and deep brain stimulation among others. That is why many of them are being adopted today as they extend new approaches to the treatment of symptoms and possible diseases, which will improve the outcomes of therapy.
- The Parkinson’s Disease Therapeutics Market is boosted by recent enhancement of investment on research and development by the pharmaceutical companies. All these investments are enabling the establishment of new drug commodities and therapeutic approaches that are expected to produce additional well-targeted treatment. The two drivers, combination therapies and new technologies including gene therapy and neuroprotective agents are also picking steam. This trend is in line with a shift to differentiate the approaches to the treatment of this illness taking into account the multifactorial character of Parkinson’s disease. Newer research and development are the future markets with referring to improved therapeutic outcomes and better management of the disease.
Advancements in Gene Therapy, Cell-Based Treatments, and Personalized Medicine
- Combination of Gene therapy and cell-based treatments has opened a new avenue in the Parkinson’s disease therapeutics market. Cue to this, the traditional approach concentrated more on managing symptoms while these new methods are meant to improve the disease. For instance, gene therapy aims at correcting defective genes related to Parkinson’s, and cell replacement therapies like stem cell therapy wants to ensure the lost functionality of neurons is regained through replacement. These advancements are not just a possibility of changing the course of the disease but also offer durable advantages making these treatments revolutionary in the market place.
- Similarly, the advent of gene targeted drugs and medicine specific to one person’s requirement is calling the shots for Parkinson’s disease treatment in the fututre. Personalised medicines have been shown to increase the levels of effectiveness and reduce the incidences of side effects since its implications increase the understanding of the genetic makeup of a patient. Moreover, promising development in the biomarker identification for diagnosis and disease progression presents a considerable potential for pharmaceutical firms. They help in the identification of the companion diagnostics which leads to targeted therapy leading to careful disease management. Such innovations do not only enhance therapeutic outcomes, but the market potential of therapeutic interventions is also boosted because the availability and accessibility of choice therapeutic interventions matches the existing patient needs in relation to their conditions.
Parkinsons Disease Therapeutics Market Segment Analysis:
Parkinsons Disease Therapeutics Market is Segmented on the basis of Drug Class, Route of Administration, Distribution Channel, and Region.
By Drug Class, Levodopa segment is expected to dominate the market during the forecast period
- Levodopa can be considered one of the most popular types of medications for neurodegenerative diseases ranging from Parkinson’s disease, first and foremost, due to its unsurpassed effectiveness in terms of restoring the content of dopamine in the brain. The exact way this drug works is that since dopamine is low, owing to the degeneration of neurons producing it, this drug itself synthesises dopamine. The verity that it helps lessen fundamental signs such as bradykinesia, rigidity, and tremors has established it as the first-line pharmacotherapy for most patients. The many years of clinical performance as well as adoptions into standard treatment regimens indicate the reliability of the therapy. They have reported that levodopa rapidly minimises the symptoms and improves the quality of life of the patients with PD in moderate to advanced stages.
- Recently the use of combination therapies involving Levodopa has improved the usage and acceptance of the product. Levodopa is usually administered alongside Carbidopa or Benserazide in order to reduce peripheral conversion of Levodopa into dopamine and therefore increase its uptake in the brain but with less side effects such as nausea and hypotension. These innovations help to continue that effectiveness, and mitigate a problem of ‘wearing off’ where the drug’s impact in alleviating symptoms is reduced before the next administration. Moreover, storage, sustained-release formulations and combination with other drugs, for example, COMT inhibitors or MAO-B inhibitors hyperfine modulation of the disease allows leaving Levodopa a cornerstone of peritumoral treatment.
By Distribution Channel, Hospital Pharmacies segment expected to held the largest share
- Inpatient pharmacy services are central in the treatment of hospitalized patients with advanced stage diseases especially when complicated by need for individualized therapeutic regimen or for use of injectables. These facilities deal with patients with multiple health requirements, especially where accurate dosage is required at all times. As with many later-stage diseases like neurodegenerative diseases, patients require specific therapies which cannot be sourced in ordinary retail shops. Hospital pharmacies are well capable to deliver these therapies meeting the time schedule of granting therapies and monitoring the response of the patients. The capacity to store and distribute high priced specialty drugs intended for the severe conditions can hardly be overestimated as their role in healthcare provision.
- The relationships with drug makers also enhance the competence of hospital pharmacies. They allow obtaining of new drugs and therapeutic regimens because such collaborations often enter into non-disclosure agreements with patients who directly receive advanced care. Thirdly, the said relations are advantageous to hospital pharmacies which secure drugs at cheaper rates hence enhancing the utilization of resources by a healthcare provider. Proving thus the fact that, hospital pharmacies not only improve patient outcomes but also take central positioning in ensuring that superb technologies being developed within factories reach their rightful destination, the patients.
Parkinsons Disease Therapeutics Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America is the largest market for Parkinson’s Disease Therapeutics globally because unlike many developing countries including those in the Asia Pacific, North America has the infrastructure to support a healthy health care system, high disease awareness and ready access to many treatment options. The United States plays a significant role, due to ongoing research and the fast-growing usage of novel treatment kinds like gene therapy and customized medicine. This progress is also complimented by the industry that boasts of quality pharma major pharmaceutical companies, that propel drug innovation and marketization. The commitment to clinical trials for Parkinson’s disease is evident through extensive and pioneering regional activities, most of which are also constantly innovating within their therapeutic spaces.
- Canada also assists the growth of market in North America via plausible governmental policies on treatment of neurodegenerative diseases. Major funds have also been dedicated on research that Canadian institution has built better diagnostics and establishing new treatments. Furthermore, raising public knowledge and wrapping healthcare services encourages a wider population to receive state-of-the-art treatment. This social commitment among government, academia and business makes North America a strategic region for developments in Parkinson’s disease treatments.
Active Key Players in the Parkinsons Disease Therapeutics Market
- AbbVie Inc.,
- Biogen Inc.,
- Boehringer Ingelheim International GmbH,
- Cipla Inc.,
- Denali Therapeutics Inc.,
- Dr. Reddy’s Laboratories,
- Eli Lilly and Company
- GlaxoSmithKline Plc.,
- Merck & Co., Inc.,
- Novartis AG,
- Prevail Therapeutics,
- Sun Pharmaceutical Industries Ltd.,
- Teva Pharmaceutical Industries Ltd.,
- Voyager Therapeutics
- Zydus Cadila,
- Other Active Players.
|
Parkinsons Disease Therapeutics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 5.46 Billion |
|
Forecast Period 2024-32 CAGR: |
7.1% |
Market Size in 2032: |
USD 10.12 Billion |
|
Segments Covered:
|
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Parkinsons Disease Therapeutics Market by Drug Class
4.1 Parkinsons Disease Therapeutics Market Snapshot and Growth Engine
4.2 Parkinsons Disease Therapeutics Market Overview
4.3 Levodopa
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Levodopa: Geographic Segmentation Analysis
4.4 Dopamine agonists
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Dopamine agonists: Geographic Segmentation Analysis
4.5 MAO-B inhibitors
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 MAO-B inhibitors: Geographic Segmentation Analysis
4.6 Anticholinergics
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Anticholinergics: Geographic Segmentation Analysis
4.7 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine: Geographic Segmentation Analysis
4.8 among Others)
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 among Others): Geographic Segmentation Analysis
Chapter 5: Parkinsons Disease Therapeutics Market by Route of Administration
5.1 Parkinsons Disease Therapeutics Market Snapshot and Growth Engine
5.2 Parkinsons Disease Therapeutics Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation Analysis
5.4 Injectable
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Injectable: Geographic Segmentation Analysis
5.5 Nasal
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Nasal: Geographic Segmentation Analysis
5.6 Transdermal
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Transdermal: Geographic Segmentation Analysis
5.7 Others (Rectal
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others (Rectal: Geographic Segmentation Analysis
5.8 Sublingual
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Sublingual: Geographic Segmentation Analysis
5.9 among Others)
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 among Others): Geographic Segmentation Analysis
Chapter 6: Parkinsons Disease Therapeutics Market by Distribution Channel
6.1 Parkinsons Disease Therapeutics Market Snapshot and Growth Engine
6.2 Parkinsons Disease Therapeutics Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
6.4 Retail Pharmacies
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail Pharmacies: Geographic Segmentation Analysis
6.5 Online Pharmacies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Parkinsons Disease Therapeutics Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 NOVARTIS AG
7.4 GLAXOSMITHKLINE PLC.
7.5 ABBVIE INC.
7.6 MERCK & CO. INC.
7.7 ZYDUS CADILA
7.8 DR. REDDY’S LABORATORIES
7.9 SUN PHARMACEUTICAL INDUSTRIES LTD.
7.10 CIPLA INC.
7.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.12 DENALI THERAPEUTICS INC.
7.13 BIOGEN INC.
7.14 PREVAIL THERAPEUTICS
7.15 ELI LILLY AND COMPANY AND VOYAGER THERAPEUTICS.
7.16 OTHER ACTIVE PLAYERS
Chapter 8: Global Parkinsons Disease Therapeutics Market By Region
8.1 Overview
8.2. North America Parkinsons Disease Therapeutics Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Class
8.2.4.1 Levodopa
8.2.4.2 Dopamine agonists
8.2.4.3 MAO-B inhibitors
8.2.4.4 Anticholinergics
8.2.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.2.4.6 among Others)
8.2.5 Historic and Forecasted Market Size By Route of Administration
8.2.5.1 Oral
8.2.5.2 Injectable
8.2.5.3 Nasal
8.2.5.4 Transdermal
8.2.5.5 Others (Rectal
8.2.5.6 Sublingual
8.2.5.7 among Others)
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospital Pharmacies
8.2.6.2 Retail Pharmacies
8.2.6.3 Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Parkinsons Disease Therapeutics Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Class
8.3.4.1 Levodopa
8.3.4.2 Dopamine agonists
8.3.4.3 MAO-B inhibitors
8.3.4.4 Anticholinergics
8.3.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.3.4.6 among Others)
8.3.5 Historic and Forecasted Market Size By Route of Administration
8.3.5.1 Oral
8.3.5.2 Injectable
8.3.5.3 Nasal
8.3.5.4 Transdermal
8.3.5.5 Others (Rectal
8.3.5.6 Sublingual
8.3.5.7 among Others)
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospital Pharmacies
8.3.6.2 Retail Pharmacies
8.3.6.3 Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Bulgaria
8.3.7.2 The Czech Republic
8.3.7.3 Hungary
8.3.7.4 Poland
8.3.7.5 Romania
8.3.7.6 Rest of Eastern Europe
8.4. Western Europe Parkinsons Disease Therapeutics Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Class
8.4.4.1 Levodopa
8.4.4.2 Dopamine agonists
8.4.4.3 MAO-B inhibitors
8.4.4.4 Anticholinergics
8.4.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.4.4.6 among Others)
8.4.5 Historic and Forecasted Market Size By Route of Administration
8.4.5.1 Oral
8.4.5.2 Injectable
8.4.5.3 Nasal
8.4.5.4 Transdermal
8.4.5.5 Others (Rectal
8.4.5.6 Sublingual
8.4.5.7 among Others)
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospital Pharmacies
8.4.6.2 Retail Pharmacies
8.4.6.3 Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 Netherlands
8.4.7.5 Italy
8.4.7.6 Russia
8.4.7.7 Spain
8.4.7.8 Rest of Western Europe
8.5. Asia Pacific Parkinsons Disease Therapeutics Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Class
8.5.4.1 Levodopa
8.5.4.2 Dopamine agonists
8.5.4.3 MAO-B inhibitors
8.5.4.4 Anticholinergics
8.5.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.5.4.6 among Others)
8.5.5 Historic and Forecasted Market Size By Route of Administration
8.5.5.1 Oral
8.5.5.2 Injectable
8.5.5.3 Nasal
8.5.5.4 Transdermal
8.5.5.5 Others (Rectal
8.5.5.6 Sublingual
8.5.5.7 among Others)
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospital Pharmacies
8.5.6.2 Retail Pharmacies
8.5.6.3 Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Parkinsons Disease Therapeutics Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Class
8.6.4.1 Levodopa
8.6.4.2 Dopamine agonists
8.6.4.3 MAO-B inhibitors
8.6.4.4 Anticholinergics
8.6.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.6.4.6 among Others)
8.6.5 Historic and Forecasted Market Size By Route of Administration
8.6.5.1 Oral
8.6.5.2 Injectable
8.6.5.3 Nasal
8.6.5.4 Transdermal
8.6.5.5 Others (Rectal
8.6.5.6 Sublingual
8.6.5.7 among Others)
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospital Pharmacies
8.6.6.2 Retail Pharmacies
8.6.6.3 Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkey
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Parkinsons Disease Therapeutics Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Class
8.7.4.1 Levodopa
8.7.4.2 Dopamine agonists
8.7.4.3 MAO-B inhibitors
8.7.4.4 Anticholinergics
8.7.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
8.7.4.6 among Others)
8.7.5 Historic and Forecasted Market Size By Route of Administration
8.7.5.1 Oral
8.7.5.2 Injectable
8.7.5.3 Nasal
8.7.5.4 Transdermal
8.7.5.5 Others (Rectal
8.7.5.6 Sublingual
8.7.5.7 among Others)
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospital Pharmacies
8.7.6.2 Retail Pharmacies
8.7.6.3 Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Parkinsons Disease Therapeutics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 5.46 Billion |
|
Forecast Period 2024-32 CAGR: |
7.1% |
Market Size in 2032: |
USD 10.12 Billion |
|
Segments Covered:
|
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
